CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

luspatercept

Last Updated: November 4, 2020
Result type: Reports
Project Number: SR0669-000
Product Line: Reimbursement Review

Generic Name: luspatercept

Brand Name: Reblozyl

Manufacturer: Celgene Inc. / Bristol-Myers Squibb Canada Co.

Therapeutic Area: beta-thalassemia associated anemia

Indications: For the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia

Manufacturer Requested Reimbursement Criteria1: ​For the treatment of adult patients with β-thalassemia associated anemia who require red blood cell (RBC) transfusions.

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: October 29, 2020

Call for patient/clinician input closed: December 17, 2020

Anticipated Date: November 26, 2020

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback